Millendo Therapeutics Inc. amongst top 5 bottom performers on NASDAQ
The National Association of Securities Dealers Automated Quotations (NASDAQ) Composite Index opened at 13,103.97 on 29th March 2021. Till 1 PM the highest it touched was 13,143.41 and lowest 12,968.16
Top 5 Bottom Performers Till 1 PM:
Millendo Therapeutics Inc. (Change -34.86% priced at $1.4)
Millendo Therapeutics is primarily focused on developing new treatments for endocrine diseases where there are significant unmet medical needs. Founded in 2012 believe in the ability to leverage scientific advances to develop novel compounds to treat complex conditions and advance clinical care. US Corporate Headquarters address is 110 Miller Avenue, Suite 100Ann Arbor,MI 48104.
Celldex Therapeutics Inc. (Change -28.38% priced at $17)
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Summer Infant Inc. (Change -27.93% priced at $15.6)
Summer Infant, Inc. designs, markets, and distributes branded infant and juvenile health, safety, and wellness products. It markets proprietary products in various product categories including nursery audio or video monitors, safety gates, durable bath products, bed rails, infant thermometers, related health and safety products, booster and potty seats, cribs, baby gear, bouncers, feeding items, and swaddling blankets. The company was founded in 1985 and is headquartered in Woonsocket, RI.
Orphazyme A/S ADR (Change -29.14% priced at $8.7)
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.
F-star Therapeutics Inc. (Change -20.48% priced at $10.2)
